Purdue Pharma (Canada)
Real World Evidence of the Efficacy and Safety of FOQUEST
- Conditions
- Attention Deficit-Hyperactivity Disorder
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 257
- Registration Number
- NCT04152629
- Locations
- 🇨🇦
Health Sciences North, Sudbury, Ontario, Canada
🇨🇦Matheson Centre for Mental Health Research & Education, University of Calgary, Calgary, Alberta, Canada
🇨🇦Alpha recherche clinique, Québec, Quebec, Canada
PENTHROX™ in the Canadian Emergency Department (ED)
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 99
- Registration Number
- NCT03868436
- Locations
- 🇨🇦
Royal Victoria Regional Health Centre, Barrie, Ontario, Canada
🇨🇦St. Joseph's Healthcare, Welland, Ontario, Canada
🇨🇦Markham Stouffville, Markham, Ontario, Canada
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 207
- Registration Number
- NCT03649230
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦Centre Integre de Sante et de Services Sociaux de la Monteregie-Centre, Greenfield Park, Quebec, Canada
🇨🇦Centre de recherche du CHUS and Hopital Fleurimont, Sherbrooke, Quebec, Canada
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- ADHD
- Interventions
- Drug: Placebo oral capsulesDrug: PRC-063 oral capsules
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 288
- Registration Number
- NCT03618030
- Locations
- 🇺🇸
Bayou City Research, Houston, Texas, United States
🇺🇸Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Meridien Research, Lakeland, Florida, United States
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
- Conditions
- ADHD
- Interventions
- Drug: Placebo oral capsulesDrug: PRC-063 oral capsules
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 156
- Registration Number
- NCT03172481
- Locations
- 🇺🇸
Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States
🇺🇸AVIDA Inc., Newport Beach, California, United States
🇺🇸Meridien Research Inc., Maitland, Florida, United States